Potential	potential	O	O	O	O
deleterious	deleterious	O	O	O	O
effect	effect	O	O	O	O
of	of	O	O	O	O
furosemide	furosemide	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
radiocontrast	radiocontrast	O	O	O	O
nephropathy	nephropathy	O	DISEASE	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
purpose	purpose	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
study	study	O	O	O	O
was	was	O	O	O	O
to	to	O	O	O	O
determine	determine	O	O	O	O
the	the	O	O	O	O
efficacy	efficacy	O	O	O	O
of	of	O	O	O	O
furosemide	furosemide	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
addition	addition	O	O	O	O
to	to	O	O	O	O
intravenous	intravenous	O	O	O	O
fluids	fluids	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
prevention	prevention	O	O	O	O
of	of	O	O	O	O
radiocontrast	radiocontrast	O	O	O	O
nephropathy	nephropathy	O	DISEASE	OTHERS	I
.	.	O	O	O	O

18	18	O	O	O	O
patients	patients	O	O	O	O
,	,	O	O	O	O
referred	referred	O	O	O	O
to	to	O	O	O	O
a	a	O	O	O	O
radiocontrast	radiocontrast	O	O	O	O
study	study	O	O	O	O
,	,	O	O	O	O
considered	considered	O	O	O	O
at	at	O	O	O	O
risk	risk	O	O	O	O
because	because	O	O	O	O
of	of	O	O	O	O
preexisting	preexisting	O	O	O	O
renal	renal	O	DISEASE	OTHERS	I
insufficiency	insufficiency	O	DISEASE	OTHERS	I
,	,	O	O	O	O
were	were	O	O	O	O
enrolled	enrolled	O	O	O	O
in	in	O	O	O	O
a	a	O	O	O	O
prospective	prospective	O	O	O	O
,	,	O	O	O	O
randomized	randomized	O	O	O	O
,	,	O	O	O	O
controlled	controlled	O	O	O	O
trial	trial	O	O	O	O
,	,	O	O	O	O
performed	performed	O	O	O	O
at	at	O	O	O	O
the	the	O	O	O	O
secondary	secondary	O	O	O	O
care	care	O	O	O	O
center	center	O	O	O	O
of	of	O	O	O	O
a	a	O	O	O	O
1,100-bed	1,100-bed	O	O	O	O
private	private	O	O	O	O
university	university	O	O	O	O
hospital	hospital	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
addition	addition	O	O	O	O
to	to	O	O	O	O
fluids	fluids	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
treatment	treatment	O	O	O	O
group	group	O	O	O	O
received	received	O	O	O	O
furosemide	furosemide	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
mean	mean	O	O	O	O
dose	dose	O	O	O	O
110	110	O	O	O	O
mg	mg	O	O	OTHERS	I
)	)	O	O	O	O
intravenously	intravenously	O	O	O	O
30	30	O	O	O	O
min	min	O	O	O	O
prior	prior	O	O	O	O
to	to	O	O	O	O
the	the	O	O	O	O
injection	injection	O	O	O	O
of	of	O	O	O	O
contrast	contrast	CHEMICALS	O	OTHERS	I
material	material	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
control	control	O	O	O	O
group	group	O	O	O	O
received	received	O	O	O	O
fluids	fluids	O	O	O	O
(	(	O	O	O	O
mean	mean	O	O	O	O
3	3	O	O	O	O
liters	liters	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Radiological	radiological	O	O	O	O
studies	studies	O	O	O	O
were	were	O	O	O	O
mostly	mostly	O	O	O	O
angiographies	angiographies	O	O	O	O
performed	performed	O	O	O	O
with	with	O	O	O	O
both	both	O	O	O	O
ionic	ionic	O	O	O	O
and	and	O	O	O	O
non-ionic	non-ionic	O	O	O	O
contrast	contrast	CHEMICALS	O	OTHERS	I
material	material	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
at	at	O	O	O	O
an	an	O	O	O	O
average	average	O	O	O	O
dose	dose	O	O	O	O
of	of	O	O	O	O
245	245	O	O	O	O
ml	ml	O	O	O	O
.	.	O	O	O	O

Renal	renal	O	O	OTHERS	I
function	function	O	O	OTHERS	I
significantly	significantly	O	O	OTHERS	I
deteriorated	deteriorated	O	O	OTHERS	I
in	in	O	O	O	O
the	the	O	O	O	O
group	group	O	O	O	O
pretreated	pretreated	O	O	O	O
with	with	O	O	O	O
furosemide	furosemide	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
p	p	O	O	OTHERS	I
<	<	O	O	O	O
0.005	0.005	O	O	O	O
by	by	O	O	O	O
ANOVA	anova	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
with	with	O	O	O	O
a	a	O	O	O	O
rise	rise	O	O	O	O
in	in	O	O	O	O
serum	serum	O	O	O	O
creatinine	creatinine	CHEMICALS	O	OTHERS	I
from	from	O	O	O	O
145	145	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
13	13	O	O	O	O
to	to	O	O	O	O
182	182	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
16	16	O	O	O	O
mumol/l	mumol/l	O	O	O	O
at	at	O	O	O	O
24	24	O	O	O	O
h	h	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
while	while	O	O	O	O
no	no	O	O	O	O
change	change	O	O	O	O
occurred	occurred	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
control	control	O	O	O	O
group	group	O	O	O	O
(	(	O	O	O	O
from	from	O	O	O	O
141	141	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
6	6	O	O	O	O
to	to	O	O	O	O
142	142	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
7	7	O	O	O	O
mumol/l	mumol/l	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Renal	renal	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
was	was	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
weight	weight	O	DISEASE	OTHERS	I
loss	loss	O	DISEASE	OTHERS	I
in	in	O	O	O	O
the	the	O	O	O	O
furosemide-treated	furosemide-treated	O	O	O	O
group	group	O	O	O	O
.	.	O	O	O	O

Furosemide	furosemide	CHEMICALS	O	OTHERS	I
may	may	O	O	O	O
be	be	O	O	O	O
deleterious	deleterious	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
prevention	prevention	O	O	O	O
of	of	O	O	O	O
radiocontrast	radiocontrast	O	O	O	O
nephropathy	nephropathy	O	DISEASE	OTHERS	I
.	.	O	O	O	O

